These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30564083)

  • 21. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
    Sun J; Li M; Wang Y; Hao P; Jin X
    Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever.
    Subramaniyan V; Venkatachalam R; Srinivasan P; Palani M
    J Biomed Res; 2017 Nov; 32(3):222-36. PubMed ID: 29497025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.
    Khanam S; Rajendra P; Khanna N; Swaminathan S
    BMC Biotechnol; 2007 Feb; 7():10. PubMed ID: 17302980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
    Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
    J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
    Zuest R; Valdes I; Skibinski D; Lin Y; Toh YX; Chan K; Hermida L; Connolly J; Guillen G; Fink K
    Vaccine; 2015 Mar; 33(12):1474-82. PubMed ID: 25659270
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Shukla R; Rajpoot RK; Arora U; Poddar A; Swaminathan S; Khanna N
    Front Microbiol; 2017; 8():2644. PubMed ID: 29367852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice.
    Kulkarni A; Bhat R; Malik M; Sane S; Kothari S; Vaidya S; Chowdhary A; Deshmukh RA
    Iran J Med Sci; 2017 Mar; 42(2):152-160. PubMed ID: 28360441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus.
    Suzarte E; Marcos E; Gil L; Valdés I; Lazo L; Ramos Y; Pérez Y; Falcón V; Romero Y; Guzmán MG; González S; Kourí J; Guillén G; Hermida L
    Arch Virol; 2014 Jul; 159(7):1629-40. PubMed ID: 24420159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen.
    Batra G; Talha SM; Nemani SK; Dhar N; Swaminathan S; Khanna N
    Protein Expr Purif; 2010 Nov; 74(1):99-105. PubMed ID: 20435144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice.
    Konishi E; Kosugi S; Imoto J
    Vaccine; 2006 Mar; 24(12):2200-7. PubMed ID: 16316713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses.
    Valdés I; Marcos E; Suzarte E; Pérez Y; Brown E; Lazo L; Cobas K; Yaugel M; Rodríguez Y; Gil L; Guillén G; Hermida L
    Arch Virol; 2017 Aug; 162(8):2247-2256. PubMed ID: 28393307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
    Tang YX; Jiang LF; Zhou JM; Yin Y; Yang XM; Liu WQ; Fang DY
    Chin Med J (Engl); 2012 Jun; 125(11):1986-92. PubMed ID: 22884066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity.
    Leng CH; Liu SJ; Tsai JP; Li YS; Chen MY; Liu HH; Lien SP; Yueh A; Hsiao KN; Lai LW; Liu FC; Chong P; Chen HW
    Microbes Infect; 2009 Feb; 11(2):288-95. PubMed ID: 19114121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein.
    Chen S; Yu M; Jiang T; Deng Y; Qin C; Qin E
    DNA Cell Biol; 2007 Jun; 26(6):361-7. PubMed ID: 17570760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.